Lantern Pharma (LTRN) Q1 2025 Earnings Call May 15, 2025 09:00 AM ET Speaker0 Good morning, and welcome to our first quarter twenty twenty five earnings call. As a reminder, this call is being recorded, and all attendees are in a listen only mode. We will open the call for questions and answers after our management's presentation. A webcast replay of today's conference call will be available on our website at lanternpharma.com shortly after the call. We issued a press release before the market opened today ...

May 15th, 2025 9AM Eastern Time First Quarter 2025 Operating & Financial Results Conference Call / Webinar 01 Introduction 02 2025 Q1 Highlights 03 Financial Highlights 04 Q&A NASDAQ :LTRN Forward Looking Statements This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements include, among other things, statements relating to: future even ...

FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Lantern Pharma Inc. (Exact name of registrant as specified in its charter) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 | Delaware | 001-39318 | 46-3973463 | | --- | --- | --- | | (State or Other Jurisdiction | (Commission | (IRS Empl ...

Exhibit 99.1 Lantern Pharma Reports First Quarter 2025 Financial Results and Business Updates FOR IMMEDIATE RELEASE DALLAS—(BUSINESS WIRE)— May 15, 2025 — Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage biopharmaceutical company leveraging its proprietary RADR artificial intelligence (AI) and machine learning (ML) platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced operational highlights and financial results for the first quarter 2025 ended Ma ...

Lantern Pharma (LTRN) Q4 2024 Earnings Call March 28, 2025 07:20 AM ET Company Participants Panna Sharma - President, Chief Executive Officer & DirectorDavid Margrave - Chief Financial Officer & Secretary Conference Call Participants None - Analyst Panna Sharma And and we were very excited to establish a scientific advisory board that, is joined by experts such as doctors Mitch Berger at UCSF, Doctor. Lisa DeAngelis at Memorial Sloan Kettering and doctors Stuart Grossman and John Latera at Johns Hopkins, al ...

Lantern Pharma Inc. (NASDAQ:LTRN) Q4 2024 Earnings Conference Call March 27, 2025 4:30 AM ET Company Participants Panna Sharma - President and CEO David Margrave - Chief Financial Officer Kishor Bhatia - Chief Scientific Officer Conference Call Participants Operator Good afternoon, and welcome to our Fourth Quarter and Year End 2024 Earnings Call. As a reminder, this call is being recorded, and all attendees are in a listen-only mode. We will open the call for questions-and-answers after our management's pr ...

Corporate Overview March 2025 NASDAQ: LTRN Forward Looking Statements This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements include, among other things, statements relating to: future events or our future financial performance; the potential advantages of our RADR® platform in identifying drug candidates and patient populations that ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Lantern Pharma Inc. (Exact name of registrant as specified in its charter) | Delaware | 001-39318 | 46-3973463 | | --- | --- | --- | | (State or Other Jurisdiction | (Commission | (IRS Employer ...

Exhibit 99.1 Lantern Pharma Provides Business Updates and Fourth Quarter & Year-End 2024 Financial Results www.lanternpharma.com Q4 & Year End 2024 Company Updates & Earnings Press Release. pp. 1 ● HARMONIC™ trial lead-in cohort delivered impressive 86% clinical benefit rate and 43% objective response rate in never- smoker NSCLC patients, with current expansion cohort reinforcing these positive trends as enrollment accelerates in Japan and Taiwan, where 33-40% of NSCLC cases occur in never-smokers, position ...

Financial Data and Key Metrics Changes - The company recorded a net loss of approximately $4.5 million for Q3 2024, compared to a net loss of approximately $3.2 million for Q3 2023, representing an increase in loss per share from $0.29 to $0.42 [27] - R&D expenses increased to approximately $3.7 million in Q3 2024 from approximately $2.2 million in Q3 2023, driven by increased clinical trial activity [27] - General and administrative expenses rose slightly to approximately $1.5 million in Q3 2024 from approximately $1.3 million in Q3 2023, primarily due to higher professional and legal fees [28] - The cash position as of September 30, 2024, was approximately $28.1 million, expected to provide a runway into at least late 2025 [29] Business Line Data and Key Metrics Changes - The company has three precision oncology drug candidates advancing through clinical trials, all guided by the RADR AI platform, with significant clinical progress reported [11][10] - The Harmonic trial for LP-300 showed an 86% clinical benefit rate in the first seven patients, indicating promising early data [12] - LP-184 and LP-284 are in Phase Ia trials, with over 50 patients dosed and no dose-limiting toxicities observed [15] Market Data and Key Metrics Changes - The expansion of the MARTA trial into Asia, specifically Japan and Taiwan, is strategically important due to the higher prevalence of never smoker lung cancer in these regions [13] - The market opportunity for LP-284 in the US and Europe is estimated to exceed $2.8 billion to $3 billion annually, targeting 16,000 to 20,000 new patients [48] Company Strategy and Development Direction - The company is focused on leveraging AI and machine learning to transform oncology drug development, aiming to reduce costs and timelines while advancing precision therapies [10][11] - The establishment of Starlight Therapeutics aims to focus on CNS and brain cancer indications, with plans for Phase Ib and II trials expected to launch in early 2025 [35][86] Management's Comments on Operating Environment and Future Outlook - Management emphasized the importance of AI in drug development, stating that the industry is undergoing a fundamental transformation [7] - The FDA's Fast Track designation for LP-184 in glioblastoma is seen as a significant milestone, potentially expediting development and increasing commercial value [37] - The company is optimistic about the future, expecting several clinical readouts and milestones in the upcoming quarters [76] Other Important Information - The company received three new FDA rare pediatric designations for LP-184, which could lead to priority review vouchers upon FDA approval [21] - The RADR AI platform has guided the development of three AI-guided drug candidates into ongoing clinical trials, showcasing the platform's effectiveness [32] Q&A Session Summary Question: When do we expect additional data regarding our HARMONIC and LP-300 trial? - The company expects to gather more data after enrolling 14 to 28 additional patients and plans an interim analysis at 31 patients, with results anticipated around mid-next year [79] Question: Any updates on how Radar is growing and collaboration efforts? - The collaboration with Oregon Therapeutics is progressing well, with expectations to finalize the first phase by the end of the year, and the company is looking at additional collaborations with larger biotech firms [80][81] Question: Can we speak to any partnership interest? - Discussions are ongoing with larger pharma companies in Japan regarding potential partnerships, particularly due to the high prevalence of non-small cell lung cancer among never smokers in East Asia [82] Question: Updates on Starlight Therapeutics and the Scientific Advisory Board members? - The company is excited about the involvement of prominent experts in the Scientific Advisory Board, which is expected to enhance the potential of their CNS cancer programs [85][86]